Gene Symbol: PARK2
Full Name: Parkin RBR E3 Ubiquitin Protein Ligase
Chromosomal Location: 6q26
NCBI Gene ID: 5071
OMIM: 600116
Ensembl ID: ENSG00000185358
UniProt ID: O60260
Associated Diseases: Parkinson's Disease, Autosomal Recessive Juvenile Parkinsonism
PARKIN (also known as PARK2) is a critical gene in the study of neurodegenerative diseases, particularly Parkinson's disease. This gene encodes the parkin protein, an E3 ubiquitin ligase essential for mitochondrial quality control. Mutations in PARKIN cause autosomal recessive juvenile parkinsonism (ARJP), characterized by early-onset Parkinson's disease with a typically slow but progressive course.
PARK2 encodes the protein parkin, an E3 ubiquitin ligase that plays a critical role in mitochondrial quality control and the pathogenesis of Parkinson's disease (PD). Mutations in PARK2 cause autosomal recessive juvenile parkinsonism (ARJP), characterized by early-onset PD with a slow but progressive course.
The PARKIN gene (also known as PARK2) encodes the parkin protein, an E3 ubiquitin ligase that plays a crucial role in mitochondrial quality control. Pathogenic mutations in PARKIN cause autosomal recessive juvenile parkinsonism (ARJP), characterized by early-onset Parkinson's disease with typically good levodopa responsiveness but progressive neurodegeneration.
Parkin is a cytosolic E3 ubiquitin ligase essential for mitochondrial maintenance and quality control. Its normal functions include:
- Mitochondrial biogenesis: Regulates mitochondrial replication and function
- Mitophagy: Tags damaged mitochondria for autophagic degradation
- Protein degradation: Targets proteins for ubiquitin-proteasome system degradation
- Synaptic function: Regulates synaptic vesicle proteins and neurotransmitter release
- Cell survival: Protects neurons from apoptotic cell death
The parkin protein (465 amino acids) contains multiple functional domains:
- N-terminal ubiquitin-like (Ubl) domain (1-76): Mediates interactions with proteasome and autophagy receptors
- RING0 domain (140-200): Regulatory domain
- RING1 domain (212-255): E2 enzyme binding
- In-between-RING (IBR) domain (321-380): E2 enzyme binding
- RING2 domain (418-465): Catalytic domain with ubiquitin ligase activity
- Early onset: Symptoms typically begin before age 20
- Slow progression: Benign course compared to sporadic PD
- Levodopa responsiveness: Good response to dopaminergic therapy
- Mitochondrial dysfunction: Primary pathological feature
- PARK2 mutations account for ~50% of early-onset familial PD
- Heterozygous mutations may be risk factors for late-onset PD
- Mitochondrial dysfunction is a key pathological feature
- Mitophagy impairment: Failure to clear damaged mitochondria
- Mitochondrial DNA mutations: Accumulation of mtDNA mutations
- Protein aggregation: Impaired clearance of misfolded proteins
- Oxidative stress: Increased ROS from dysfunctional mitochondria
- Synaptic dysfunction: Impaired neurotransmitter release
- Neuronal death: Progressive loss of dopaminergic neurons
- Gene therapy: AAV-mediated PARKIN delivery
- Mitophagy enhancers: Small molecules promoting mitochondrial clearance
- Antioxidants: Targeting oxidative stress
- Neuroprotective agents: Supporting neuron survival
- Mitochondrial supplements: CoQ10, creatine, and related compounds
- Kitada T, et al. (1998). "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." Nature. 392(6676):605-608. DOI:10.1038/33416
- Shimura H, et al. (2000). "Ubiquitination of a new form of alpha-synuclein by parkin." Nature. 406(6796):863-867. DOI:10.1038/35022584
- Narendra D, et al. (2008). "p62/SQSTM1 is required for parkin-induced mitochondrial clustering but not mitophagy." Autophagy. 4(6):706-708. DOI:10.4161/auto.6386
- Pickrell AM, et al. (2015). "Endogenous Parkin Preserves Mitochondrial Function during Cellular Stress." Neuron. 88(2):286-299. DOI:10.1016/j.neuron.2015.09.022
The study of Parkin Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kitada T, et al. "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." Nature. 1998;392(6676):605-608. DOI:10.1038/33416
- Shimura H, et al. "Ubiquitination of a new form of alpha-synuclein by parkin." Nature. 2000;406(6796):863-867. DOI:10.1038/35022584
- Narendra D, et al. "p62/SQSTM1 is required for parkin-induced mitochondrial clustering but not mitophagy." Autophagy. 2008;4(6):706-708. DOI:10.4161/auto.6386
- Pickrell AM, et al. "Endogenous Parkin Preserves Mitochondrial Function during Cellular Stress." Neuron. 2015;88(2):286-299. DOI:10.1016/j.neuron.2015.09.022
- Zhang C, et al. "Parkin functions as an E2-dependent ubiquitin-protein ligase." J Biol Chem. 2000;275(40):31743-31749. DOI:10.1074/jbc.M003557200
- Dawson TM, Dawson VL. "The role of parkin in Parkinson's disease." J Clin Invest. 2003;111(2):145-147. DOI:10.1172/JCI17546
- Exner N, et al. "The mitochondrial complexity of Parkinson's disease." J Neural Transm (Vienna). 2012;119(9):1023-1027. DOI:10.1007/s00702-012-0784-3
- Scarffe LA, et al. "Parkin and PINK1: much more than mitophagy." Autophagy. 2014;10(5):886-888. DOI:10.4161/auto.28506